Short Interest in Pharming Group (NASDAQ:PHAR) Decreases By 20.4%

Pharming Group (NASDAQ:PHAR) was the recipient of a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 20,300 shares, a drop of 20.4% from the November 15th total of 25,500 shares. Based on an average daily trading volume, of 6,900 shares, the short-interest ratio is presently 2.9 days.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PHAR. Jefferies Financial Group assumed coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price objective for the company. Oppenheimer decreased their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Wednesday.

Pharming Group Stock Down 3.6 %

Shares of NASDAQ:PHAR traded down $0.34 during midday trading on Friday, reaching $8.98. The company had a trading volume of 2,978 shares, compared to its average volume of 5,220. The stock has a market capitalization of $609.31 million, a P/E ratio of -34.55 and a beta of 0.05. The stock’s fifty day moving average price is $8.27 and its 200-day moving average price is $8.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a one year low of $6.65 and a one year high of $13.20.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 75.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 41,110 shares of the company’s stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.